OC
BIO icon

Oppenheimer & Co’s Bio-Rad Laboratories Class A BIO Stock Holding History

Oppenheimer & Co’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,377
Closed -$787K – 1511
2021
Q1 		$787K Buy
+1,377
New +$815K 0.02% 784

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Oppenheimer & Co's BIO Position: Q2 2021 in Review

Oppenheimer & Co sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2021, closing a stake of 1,377 shares — an estimated $787K sold.

Oppenheimer & Co first reported a position in BIO in Q1 2021 and held it in 1 quarter. The position peaked at $787K in Q1 2021. 508 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

  • Oppenheimer & Co reported no remaining Bio-Rad Laboratories Class A position as of Q2 2021 after selling out during the quarter.
  • Oppenheimer & Co sold 1,377 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $787K.
  • Oppenheimer & Co first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and held it in 1 quarter.
  • Oppenheimer & Co's Bio-Rad Laboratories Class A position peaked at $787K in Q1 2021.
  • 508 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on Oppenheimer & Co's 13F filing for Q2 2021, filed 3 Aug 2021.